impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Full Papers

 

Application of lupus comprehensive disease control in newly diagnosed systemic lupus erythematosus patients: results from the Italian multicentre Early Lupus Project inception cohort

1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23

 

  1. Reumatologia, Dipartimento di Scienze Cliniche Internistiche Anestesiologiche e Cardiovascolari, Sapienza Università di Roma, Italy. fulviaceccarelli@gmail.com
  2. Dipartimento di Scienze Mediche e Sanità Pubblica, Università degli Studi di Cagliari, Italy.
  3. Reumatologia, Dipartimento di Scienze Cliniche Internistiche Anestesiologiche e Cardiovascolari, Sapienza Università di Roma, Italy.
  4. UOC di Reumatologia, Azienda Ospedaliera San Camillo Forlanini, Roma, Italy.
  5. Dipartimento di Scienze Mediche e Sanità Pubblica, Università degli Studi di Cagliari, Italy.
  6. Dipartimento dell'Emergenza e dei Trapianto di Organi, Sezione di Reumatologia, Università degli Studi di Bari Aldo Moro Scuola di Medicina, Bari, Italy.
  7. Dipartimento dell'Emergenza e dei Trapianto di Organi, Sezione di Reumatologia, Università degli Studi di Bari Aldo Moro Scuola di Medicina, Bari, Italy.
  8. UOC e Sezione di Reumatologia, Azienda Ospedaliero-Universitaria S. Anna, Ferrara, Dipartimento di Scienze Mediche, Università degli Studi di Ferrara, Italy.
  9. UOC e Sezione di Reumatologia, Azienda Ospedaliero-Universitaria S. Anna, Ferrara, Dipartimento di Scienze Mediche, Università degli Studi di Ferrara, Italy.
  10. Reumatologia, Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa; and U.O. Reumatologia, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
  11. U.O. Reumatologia, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
  12. Rheumatology Unit, Department of Medicine - DIMED, Università degli Studi di Padova, Italy.
  13. Rheumatology Unit, Department of Medicine - DIMED, Università degli Studi di Padova, Italy.
  14. Dipartimento di Scienze Cliniche e Sperimentali, Università degli Studi di Brescia, Italy.
  15. Dipartimento di Scienze Cliniche e Sperimentali, Università degli Studi di Brescia, Italy.
  16. Università degli Studi di Siena, Italy.
  17. Università degli Studi di Siena, Italy.
  18. Epidemiology Unit, Italian Society of Rheumatology, Milano, Italy.
  19. Epidemiology Unit, Italian Society of Rheumatology, Milano, Italy.
  20. Epidemiology Unit, Italian Society of Rheumatology, Milano, Italy.
  21. Epidemiology Unit, Italian Society of Rheumatology, Milano, Italy.
  22. UOC di Reumatologia, Azienda Ospedaliera San Camillo Forlanini, Roma, Italy.
  23. Reumatologia, Dipartimento di Scienze Cliniche Internistiche Anestesiologiche e Cardiovascolari, Sapienza Università di Roma, Italy.

on behalf of the study group on Early SLE of the Italian Society of Rheumatology

CER18354
2026 Vol.44, N°3
PI 0462, PF 0467
Full Papers

purchase article

PMID: 41562361 [PubMed]

Received: 19/11/2024
Accepted : 08/04/2025
In Press: 15/01/2026
Published: 11/03/2026

Abstract

OBJECTIVES:
The concept of Comprehensive Disease Control (CDC) underlines as the control of disease activity should be associated with damage inhibition. Recently, this concept has been proposed in Systemic Lupus Erythematosus (SLE) patients (LupusCDC) with long-standing disease. In the present analysis we evaluated the incidence of LupusCDC in a cohort of newly diagnosed patients.
METHODS:
We analysed data from the multicentre cohort of the Early Lupus Project. Disease activity was evaluated by ECLAM and chronic damage by SDI. At each available time point, the presence of remission condition was assessed, defined as: Complete remission in GCs (GCon): ECLAM=0, antimalarials and/or immunosuppressants, PDN ≤5 mg/day; and Complete remission without GCs (GCoff): ECLAM=0, antimalarials and/or immunosuppressants. The presence of LupusCDC was analysed, defined as remission in the absence of progression of chronic damage (LupusCDC-GCon and LupusCDC-GCoff).
RESULTS:
We included 239 patients [205F; mean±DS age 45.8±14.6 years] with a follow-up of 36 months. During this period, 33.08% of patients achieved LupusCDC-GCon, while 12.03% LupusCDC-GCoff in at least one evaluation. Univariate analysis showed the association between failure to achieve LupusCDC-GCon and musculoskeletal manifestations (p<0.001), activity in renal and neuropsychiatric domains (p=0.01, p<0.001, respectively), association confirmed by the multivariate analysis.
CONCLUSIONS:
CDC in early onset SLE is not uncommon. Indeed, one-third of patients achieved LupusCDC-GCon in at least one evaluation. More severe disease, characterised by active renal and neuropsychiatric manifestations represented a risk factor for failure to achieve LupusCDC. The lower incidence of LupusCDC-GCoff suggested the difficulty in discontinuing GC treatment in early disease phase.

DOI: https://doi.org/10.55563/clinexprheumatol/dagoie

Rheumatology Article

Rheumatology Addendum